Press Room

  The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased Hovione and H&T Presspart have entered into a strategic partnership to advance the development of Presspart's Sunriser Capsule-based Dry Powder Inhaler platform.  The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to develop the Sunriser Dry Powder Inhaler. This innovative and best-in-class capsule-based platform is flexible enough to address both the challenges of classic carrier-based and spray-dried engineered formulations. This partnership is an extension of a successful collaboration that has spanned several years on developing and commercialising innovative dry powder inhalation devices. As part of the joint development agreement, Hovione will exclusively partner with Presspart to exploit the Sunriser device in the field of engineered formulations for dry powder inhalation.  Presspart will remain responsible for the manufacturing of the Sunriser device. To provide further insights into the benefits of this partnership for the industry, a joint workshop will be held on May 3, at the Respiratory Drug Delivery (RDD) Europe 2023. "New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,” said Dr Jean-Luc Herbeaux, Hovione’s CEO. He added: “We are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”  Christian Kraetzig, President of H&T Presspart, commented: “Following our successful collaboration with Hovione on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with Hovione in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology.” Pharmaceutical companies partnering with Hovione to develop their new inhalable drugs using the Sunriser device can leverage Hovione´s unparalleled expertise in inhalable APIs, formulation, filling, and analytical characterisation.  Additionally, with H&T Presspart's state-of-the-art device manufacturing and supply, from lab to commercial cGMP scale, companies can benefit from a comprehensive approach to drug development. This partnership enables pharmaceutical companies to access top-notch expertise and cutting-edge technology, ensuring the successful development and commercialisation of innovative inhalable drugs.    Read the article at manufacturingchemist.com  

Press Clipping

Hovione and Presspart extend technology partnership

May 03, 2023

Lisbon, March 22nd, 2023 – Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s expertise in 3D screen printing, based on their SPID®-Technology, with Hovione’s product & process development, engineering and manufacturing expertise in pharmaceutical applications. Under the terms of the agreement, Hovione will establish the Laxxon Medical 3D screen printing technology at Hovione’s cGMP production sites first in Portugal and later in the USA.  The 3D technology displays numerous advantages including the potential to produce unique or customized dosage forms with characteristics that cannot be achieved with conventional dosage forms, the ability to create tablets of any shape and size, the option to easily adjust the number of active substances and individual components in the composition of the tablet and even to set the dosage individually for each patient for personalized medicines. “Laxxon is thrilled to establish a long-term partnership with Hovione.” said Klaus Kuehne, COO of Laxxon Medical. “This partnership will serve as a great accelerator in establishing 3D screen printing within the pharmaceutical industry thus accelerating our ability to serve our customers.” “Hovione has a global reputation for their pharmaceutical innovation services, expertise and market access. This agreement marks a significant milestone for Laxxon in terms of our own market strategy and development efforts.” said Helmut Kerschbaumer, Laxxon’s CEO. “We are looking forward to collaborating with Hovione to promote innovation through 3D screen printing.”  “We find the Laxxon Medical 3D printing technology to be very innovative and enabling. It not only allows for the customization and production of drug products with complex shapes and structures as well as unique API release characteristics but it also has the potential to reduce the time and cost of drug development” says Dr. Jean-Luc Herbeaux, Hovione´s CEO. He adds “Hovione has a track record of turning emerging pharmaceutical production technologies into reliable and scalable offerings at both developmental and commercial scales. We are excited at the prospect of supporting Laxxon in industrializing its 3D printing technology and make it accessible to a greater number of pharmaceutical and medical device companies.” With this partnership the platform will be available from early development phases to routine commercial manufacturing.        About Laxxon Medical Laxxon Medical is a pharma-technology company pioneering patented cutting-edge 3D screen printing development and manufacturing solutions for the pharmaceutical industry. Laxxon’s SPID®-Technology (Screen Printing Innovational Drug Technology) facilitates different pharmaceutical forms of application such as oral, transdermal, and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients, enabling different release profiles such as sequential release. SPID®-Technology is capable of printing small batches for R&D, up to commercial-scale production without the need to change the manufacturing process. SPID®-Technology (3D Screen Printing) SPID®-Technology (Screen Printed Innovative Drug Technology) is an additive manufacturing process which enables the development and production of complex formulations and geometrical structures of oral dosage forms to optimize the release profiles of common pharmaceuticals in addition to new drug developments.    About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.    

Press Release

Hovione and Laxxon Medical Establish an Agreement for the cGMP Production of 3D Screen Printed Pharmaceutical Applications

Mar 22, 2023

  The move is set to expand the use of Ripple's Epidel platform beyond ophthalmic applications Hovione, specialist in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel platform beyond ophthalmic applications.  The core feature of Ripple’s Epidel technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry. “The combination of technology synergy, innovative vision and cultural fit makes collaborating with Hovione an exciting next step in the advancement of the Epidel platform beyond the ophthalmic field,” stated Dr Wendy Naimark, Ripple co-founder and Chief Technology Officer. “Hovione’s expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.” "We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," said Dr Jean-Luc Herbeaux, Hovione's CEO. "Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide."    Read the article at manufacturingchemist.com  

Press Clipping

Hovione enters partnership with Ripple Therapeutics

Mar 21, 2023

Lisbon, March 20, 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications.    The core feature of Ripple’s Epidel® technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel® platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry.   “The combination of technology synergy, innovative vision and cultural fit makes collaborating with Hovione an exciting next step in the advancement of the Epidel® platform beyond the ophthalmic field,” stated Dr. Wendy Naimark, Ripple co-founder and Chief Technology Officer. “Hovione’s expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.”   "We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. Jean-Luc Herbeaux, Hovione's CEO. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide." By extending the use of the Epidel® platform beyond ocular applications, this partnership will enable the development of a diverse range of new products with optimal sustained release profiles.    ​​​​​About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About Ripple Therapeutics Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com    

Press Release

Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space

Mar 20, 2023

Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). Hovione was given additional recognition as a CDMO Leadership Award Champion in the categories of Compatibility and Expertise for scoring as a top performer in comparison to the weighted average of other CDMOs included in the Industry Standard Research (ISR)’s annual Contract Manufacturing Quality Benchmarking survey.  Established in 2011 by Outsourced Pharma and Life Science Leader, the CDMO Leadership Awards spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The CDMO Leadership Awards teamed up with ISR to determine the award recipients – 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.  “We are honored and proud to receive this award in all six categories. This broad recognition reflects the dedication of our team to help our customers deliver much-needed medicines to the market,” said Dr. Jean-Luc Herbeaux, Hovione’s CEO. “This is not the first time Hovione is recognized by the CDMO Leadership awards and winning these awards once again reinforces our commitment to excellence and differentiation in the services we provide to our customers.”  “For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing,” said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma. Hovione has been expanding worldwide, demonstrating the commitment to its customers. Hovione has been investing in new laboratory and production assets and innovative technologies to meet customer demand for integrated and differentiated services in manufacturing of drug substances, particles and drug products.    Read the entire article at Teknoscienze.com     

Press Clipping

Hovione receives the 2023 CDMO Leadership Award in all six categories and is champion in Compatibility and Expertise

Mar 14, 2023

Lisbon, March 8th, 2023 – Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). Hovione was given additional recognition as a CDMO Leadership Award Champion in the categories of Compatibility and Expertise for scoring as a top performer in comparison to the weighted average of other CDMOs included in the Industry Standard Research (ISR)’s annual Contract Manufacturing Quality Benchmarking survey.  Established in 2011 by Outsourced Pharma and Life Science Leader, the CDMO Leadership Awards spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The CDMO Leadership Awards teamed up with ISR to determine the award recipients - 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.  "We are honored and proud to receive this award in all six categories. This broad recognition reflects the dedication of our team to help our customers deliver much-needed medicines to the market," said Dr. Jean-Luc Herbeaux, Hovione’s CEO. “This is not the first time Hovione is recognized by the CDMO Leadership awards and winning these awards once again reinforces our commitment to excellence and differentiation in the services we provide to our customers.”  “For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing.” Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. Hovione has been expanding worldwide, demonstrating the commitment to its customers. Hovione has been investing in new laboratory and production assets and innovative technologies to meet customer demand for integrated and differentiated services in manufacturing of drug substances, particles and drug products.  ​​​​​​ ​​​​​About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.  

Press Release

Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise

Mar 07, 2023

January 17, 2023, the companies certified as 2023 Top Employers have just been announced and Hovione has been recognized as Top Employer in Portugal, the United States of America and Ireland, geographies that encompass 90% of Hovione´s employee population. The Hovione site in Macau was purposely not included in the evaluation due to COVID-related restrictions.     This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering. Hovione’s People Strategy roadmap is focused on attracting and retaining the best to support the company´s business ambitions, and on providing employees and managers with a positive and rewarding work experience.   The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers six domains covering 20 topics including People Strategy, Work Environment, Talent Acquisition, Learning, Diversity, Equity & Inclusion and Wellbeing, amongst others.   "Receiving this certification is a great motivator for the entire organization and most particularly for our HR Team which has been focusing on establishing best practices and on delivering on our people agenda. It is the confirmation that, as an organization, we are on the right path to make the difference. We understand that while we are not yet excellent in all dimensions, we are committed to maintaining a process of continuous improvement, by putting our people at the center of everything we do, always!" - commented Ilda Ventura, Vice-President for Human Resources and Member of the Management Board at Hovione.   Portugal Catarina Tendeiro, HR Senior Director for Portugal, highlights that “We are delighted to be recognized as a Top Employer. Hovione employees are our greatest asset and to know that our programs and culture meet such a high standard is illustrative of our commitment to the team. We strive to be an employer of choice through competitive pay, meaningful work, and an attractive company culture. At Hovione Portugal, our primary focus has been on attracting and retaining talent to develop our leadership capabilities. Over the last years we have increased pay levels and most recently, provided a special inflation bonus to counter the impact of inflation on our employees. These are just a few examples of how we put our employees in the center of what we do.”  This recognition comes after Hovione received the Randstad Employer Brand Award 2022 as the most attractive company to work for in Portugal in Healthcare, ranking 5th nationally across industries.     Ireland For Imelda Cummins, HR Director for Hovione Ireland, “This recognition underlines our belief that our people are our strongest asset and competitive advantage. At Hovione Ireland we work consistently to ensure competitive compensation and benefits, invest in the creation of a healthy work environment, promote regular wellbeing initiatives and most importantly, to improve, we listen!”     United States of America Beth Swiezkowski, HR Senior Director for Hovione in New Jersey adds, “We are delighted to be recognized as a Top Employer. Hovione employees are our greatest asset and to know that our programs and culture meet such a high standard is illustrative of our commitment to the team. We strive to be an employer of choice through competitive pay, meaningful work, and an attractive company culture. Over the last year we have increased pay levels and most recently, provided a special inflation bonus to counter the impact of inflation on our employees. We focused on employee well-being and engaged experts to deliver programs on managing stress, nutrition, and healthy eating and provided free healthy snacks daily. A paid full week shutdown was also added to our holiday schedule to ensure employees had time to relax and rest with their families at the end of the year. These are just a few examples of how we put our employees in the center of what we do.”       About Hovione Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China as well as development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solution across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and delivery. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About Top Employers Institute Top Employers Institute is the global authority on recognising excellence in People Practices. They help accelerate these practices to enrich the world of work. Through the Top Employers Institute Certification Programme, participating companies can be validated, certified, and recognised as an employer of choice. Established over 30 years ago, Top Employers Institute has certified 2052 organisations in 121 countries/regions. These certified Top Employers positively impact the lives of over 9.5 million employees globally.       

Press Release

Hovione is recognized as a Top Employer 2023

Jan 17, 2023

  The two companies, who had previously established a customer-supplier relationship, have created an agreement to advance the technology and to encourage adoption. Hovione and GEA will work together on continuous tableting technology, pairing the former's development and manufacturing expertise with the latter's engineering capabilities. In terms of their respective capacities, Hovione is a contract development and manufacturing organization (CDMO) providing services for drug substance and drug product. GEA is a supplier for systems and components for the pharmaceutical industry, as well as the food and beverage industry. The aim of the partnership is to accelerate the adoption of continuous tableting technology, and also to contribute to the establishment of new standards and market acceptance of the technology, the two companies stated. In looking to promote continuous processes, the companies outlined that such systems allow for leaner and risk-reduced development paths, streamlined supply chains, increased built-in quality, and that the manufacturing processes themselves have greater flexibility and reduced complexity. Both companies have been working in the continuous manufacturing space for a number of years. Nearly a decade ago, GEA began working with the US Food and Drug Administration (FDA) to validate continuous manufacturing, with the company stating at the time that the arrangement marked the "start of the end of batch manufacturing". For Hovione, the company stated that it has been actively working on developing continuous tableting solutions for the last seven years, and it recently invested in the technology within its own manufacturing network. In September 2022, Hovione announced that it had opened a new continuous manufacturing line at its Loures site, in Portugal. At the same time as the new line, the company established a multi-disciplinary global team specialized in continuous tableting. On its latest move in the continuous tableting space, Hovione's CEO, Jean-Luc Herbeaux, stated, "Hovione has a track record in industrializing and democratizing emerging pharmaceutical technologies, such as amorphous solid dispersions by spray drying, and turn them into dependable and scalable offerings that are available to all... This collaboration with GEA, gives us the opportunity to link up with a leading designer and supplier of continuous tableting equipment solutions and bring continuous tableting to the next levels of reliability, flexibility and adoption". In a recent interview with Outsourcing-Pharma, Bikash Chatterjee, CEO of Pharmatech Associates, stated that there is a growing momentum behind the switch to continuous manufacturing, even though this has been spoken of for a number of years. Chatterjee noted that one aspect that could accelerate this shift is the national policy in the US to increase the manufacturing of certain pharmaceuticals on home soil. As a result, more efficient manufacturing, such as continuous, will be required to make the process commercially viable.   Read the entire article at Outsourcing-Pharma.com    

Press Clipping

Hovione and GEA aim to increase adoption of continuous tableting

Jan 04, 2023

Lisbon, December 14, 2022, Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner to accelerate the adoption of Continuous Tableting technology. The advantages of continuous over batch manufacturing are well known. Continuous production systems allow for leaner and risk-reduced development paths, leaner supply chains, increased built-in quality, and in general, manufacturing processes of greater flexibility and reduced complexity. In the context of this strategic collaboration, Hovione and GEA will combine their strengths to further advance the technology and contribute to the establishment of new standards and new levels of market acceptance.  “Hovione has a track record in industrializing and democratizing emerging pharmaceutical technologies, such as amorphous solid dispersions by spray drying, and turn them into dependable and scalable offerings that are available to all.” Says Jean-Luc Herbeaux, CEO of Hovione. He adds “We have been committed to Continuous Tableting for the last 7 years and we are now ready to contribute decisively to the advancement of one of the most promising technologies in pharma manufacturing. This collaboration with GEA, gives us the opportunity to link up with a leading designer and supplier of Continuous Tableting equipment solutions and bring Continuous Tableting to the next levels of reliability, flexibility and adoption.”  Navin Lakhanpaul, Global Head Pharma-Solid Dosage, GEA, adds: “As a leading supplier of process technology, GEA has established itself as a trusted solution provider in the pharmaceutical industry, and as a pioneer in the development of Continuous Tableting technology.” He adds “Our relationship with Hovione over many years has clearly demonstrated the value in further collaborating and developing synergies in our respective areas of expertise. We share a common objective of enabling the wider use of Continuous Tableting in the Pharmaceutical Industry, and firmly believe that our partnership with Hovione will accelerate the growth of this exciting technology."     About Hovione: Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of and services, from API, formulation development and devices. Hovione was the first Chemical/ Pharmaceutical Company to became a Certified B Corp, is a member of Rx-360, EFCG and participates actively in the industry standard setting process.   About GEA: GEA is one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology¬ group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components, and comprehensive services. With more than 18,000 employees working across five divisions and 62 countries, the group generated revenues of more than EUR 4.7 billion in fiscal year 2021. GEA plants, processes, components and services enhance the efficiency and sustainability of production processes across the globe. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company’s purpose: "Engineering for a better world". GEA is listed in the German MDAX and the STOXX® Europe 600 Index and is also among the companies comprising the DAX 50 ESG and MSCI Global Sustainability Indices.     Learn more about Continuous Tableting at Hovione  

Press Release

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

Dec 14, 2022

Contact Us

If you would like to learn more about Hovione, kindly fill in the form below and we will be revert to you soon.